Clinical characteristics and survival outcomes of TFE3-rearranged renal cell carcinoma: a retrospective study compared with clear cell renal cell carcinoma using propensity score matching
Authors:
Open Access
- 31 October 2025
- journal article
- research article
- Published by Springer Nature in World Journal of Urology
- Vol. 43 (1) , 1-8
Abstract
Section Background TFE3-rearranged renal cell carcinoma (TFE3-rRCC) is a rare subtype of RCC. This study aims to compare the clinical characteristics and survival outcomes with clear cell RCC (ccRCC) and explore the feasibility of partial nephrectomy (PN) in early-stage TFE3-rRCC patients. AbstractSection Materials and Patients This retrospective cohort study included 62 patients with TFE3-rRCC who underwent surgical resection at Peking University First Hospital between 2016 and 2024. Propensity score matching (PSM) was applied to match TFE3-rRCC patients with ccRCC patients. Clinical characteristics and survival outcomes were compared between the two groups. AbstractSection Results The median age of TFE3-rRCC patients at diagnosis was 33.0 years, with a female predominance (61.3%). The majority of patients were asymptomatic (61.3%). Before PSM, TFE3-rRCC patients were significantly younger and had a higher proportion of pT > 2 tumors compared to ccRCC patients (P < 0.01). After 1:2 PSM, survival outcomes in terms of progression-free survival (PFS) and overall survival (OS) were comparable between TFE3-rRCC and ccRCC in early-stage tumors. In patients with T > 2 tumors, a trend toward worse PFS was observed in the TFE3-rRCC group, though it did not reach statistical significance (P = 0.08). No significant differences in PFS and OS were observed between TFE3-rRCC and ccRCC for patients undergoing PN. AbstractSection Conclusion TFE3-rRCC should be stratified for a more accurate prognosis. Early-stage TFE3-rRCC demonstrates survival outcomes similar to those of ccRCC, and partial nephrectomy is a viable treatment approach for these patients.Keywords
Funding Information
- National High Level Hospital Clinical Research Funding (No.2024IR32)
- Beijing Research Ward Excellent Program (No. BRWEP2024W054070104)
This publication has 24 references indexed in Scilit:
- European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 UpdateEuropean Urology, 2025
- Prognostic implications and diagnostic significance of TFE3 rearrangement in renal cell carcinomaWorld Journal of Urology, 2024
- A genetic basis for sex differences in Xp11 translocation renal cell carcinomaCell, 2024
- Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2024
- Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classificationCancer Treatment Reviews, 2023
- MiT translocation renal cell carcinoma: A review of the literature from molecular characterization to clinical managementBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2022
- TFE3 and TFEB-rearranged renal cell carcinomas: an immunohistochemical panel to differentiate from common renal cell neoplasmsVirchows Archiv, 2022
- Integrative clinical and molecular characterization of translocation renal cell carcinomaCell Reports, 2022
- The classification of pediatric and young adult renal cell carcinomas registered on the children's oncology group (COG) protocol AREN03B2 after focused genetic testingCancer, 2018
- Clinicopathologic Characteristics and Prognosis of Xp11.2 Translocation Renal Cell Carcinoma: Multicenter, Propensity Score Matching AnalysisClinical Genitourinary Cancer, 2017